TD2 and Medidata Partner in ClinOps
Medidata, a Dassault Systèmes company, has announced that Translational Drug Development (TD2), a precision oncology contract research organization, has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions, offerings within Medidata’s Unified Platform.
Rave CTMS aims to address struggles that study teams experience in trying to manage and oversee clinical trials due to the fragmented and rapidly changing trial ecosystem. In 2021, Medidata released enhancements to Rave CTMS including ad hoc reporting and proactive risk management support.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
